Tumor necrosis factor receptor 1 (TNFR1)–soluble tumor necrosis factor (sTNF) trimer signaling complex (TNFR1–sTNF complex)

The Tumor necrosis factor receptor 1 (TNFR1)–soluble tumor necrosis factor (sTNF) trimer signaling complex is a pivotal molecular assembly that governs systemic inflammation and cell fate (UniProt P19438, P01375). Soluble TNF (sTNF) is generated through the proteolytic cleavage of membrane-bound TNF by the TNF-alpha converting enzyme (TACE) and exists as a bioactive homotrimer (PubMed: 21623357). Upon binding to TNFR1, the sTNF trimer induces receptor clustering and the recruitment of intracellular adaptor proteins such as TRADD and RIPK1 to form signaling Complex I. This complex initiates downstream cascades, including the NF-κB and MAPK pathways, which promote the expression of pro-inflammatory genes (PubMed: 29109463). Alternatively, the complex can transition into secondary complexes that trigger apoptosis or necroptosis. Because sTNF signals predominantly through TNFR1, this complex is a primary driver of chronic inflammatory diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease (StatPearls: TNF Inhibitors). Pharmacological intervention typically involves the use of TNF inhibitors, such as adalimumab or etanercept, which sequester sTNF to prevent complex formation, or experimental TNFR1-specific antagonists like atrosimab designed to reduce toxicity associated with global TNF blockade.

Other names

TNFRSF1A–TNF complexCD120a–TNF complexTNF–TNFR1 signaling complexSoluble TNF–TNFR1 complex

Neutralization of soluble TNF trimers to prevent binding and activation of TNFR1, or direct antagonism of the TNFR1 receptor to block downstream pro-inflammatory and apoptotic signaling pathways.